-+ 0.00%
-+ 0.00%
-+ 0.00%

Aardvark Therapeutics Q3 EPS $(0.88) Misses $(0.77) Estimate

Benzinga·11/13/2026 11:26:55
Listen to the news
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.77) by 14.29 percent. This is a 17.33 percent decrease over losses of $(0.75) per share from the same period last year.